Wall Street analysts expect that Tilray Inc (NASDAQ:TLRY) will announce earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Tilray’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.21). Tilray posted earnings per share of ($0.29) during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The business is scheduled to report its next quarterly earnings report on Monday, March 16th.
On average, analysts expect that Tilray will report full-year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.48) to ($1.09). For the next financial year, analysts forecast that the company will post earnings of ($0.94) per share, with EPS estimates ranging from ($1.56) to ($0.63). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Tilray.
Tilray (NASDAQ:TLRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05). Tilray had a negative net margin of 97.39% and a negative return on equity of 40.30%. The firm had revenue of $51.10 million during the quarter, compared to analyst estimates of $49.57 million. During the same quarter last year, the company earned ($0.08) EPS. The company’s quarterly revenue was up 411.0% compared to the same quarter last year.
NASDAQ:TLRY traded up $0.23 during mid-day trading on Thursday, reaching $19.25. 829,683 shares of the stock were exchanged, compared to its average volume of 1,884,188. The business has a fifty day moving average price of $21.63 and a 200 day moving average price of $33.49. The firm has a market capitalization of $1.99 billion, a PE ratio of -23.47 and a beta of 4.07. Tilray has a 1-year low of $18.73 and a 1-year high of $109.35. The company has a current ratio of 2.54, a quick ratio of 1.69 and a debt-to-equity ratio of 1.05.
A number of hedge funds have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC boosted its holdings in Tilray by 47.5% in the second quarter. Commonwealth Equity Services LLC now owns 26,599 shares of the company’s stock valued at $1,238,000 after acquiring an additional 8,570 shares during the last quarter. Commerzbank Aktiengesellschaft FI purchased a new position in Tilray in the 2nd quarter worth approximately $239,000. Traynor Capital Management Inc. purchased a new position in Tilray in the 2nd quarter worth approximately $347,000. Stelac Advisory Services LLC bought a new stake in Tilray in the second quarter valued at approximately $3,000,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Tilray in the second quarter valued at approximately $70,000. Institutional investors own 8.70% of the company’s stock.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.